Try
GSK plc
GSKUnited KingdomAlso United States · GSK
20 filed reports · 1,004 financial concepts · 42 earnings calls · 4 media appearances
Filed reports
20 reports · Dec 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · ACSFCA National Storage Mechanism | 5 | 1,082 | Dec 2021 to Dec 2025 |
| Annual · 20-FSEC EDGAR | 8 | 6,522 | Dec 2018 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 6 | 54 | Jun 2025 to Jun 2026 |
| Annual · 20-F/ASEC EDGAR | 1 | 717 | Dec 2017 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 6-K | Jun 30, 2026 | Sep 8, 2026 | 10 | Open |
| FY2026 Q2 | 6-K | Jun 30, 2026 | Jul 28, 2026 | 9 | Open |
| FY2026 Q1 | 6-K | Mar 31, 2026 | Apr 29, 2026 | 10 | Open |
| FY2025 | 20-F | Dec 31, 2025 | Mar 6, 2026 | 1,464 | Open |
| FY2025 | ACS | Dec 31, 2025 | Mar 5, 2026 | 277 | Open |
| FY2025 Q4 | 6-K | Dec 31, 2025 | Feb 4, 2026 | 10 | Open |
| FY2025 Q3 | 6-K | Sep 30, 2025 | Oct 29, 2025 | 10 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Jul 30, 2025 | 5 | Open |
| FY2024 | 20-F | Dec 31, 2024 | Mar 3, 2025 | 765 | Open |
| FY2024 | ACS | Dec 31, 2024 | Feb 27, 2025 | 235 | Open |
| FY2023 | 20-F | Dec 31, 2023 | Mar 5, 2024 | 754 | Open |
| FY2023 | ACS | Dec 31, 2023 | Mar 1, 2024 | 328 | Open |
Financial data
1,004 concepts · 8,375 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial816 concepts · 6,555 facts · Dec 2015 to Jun 2026
- Net debt29 · Dec 2016 to Dec 2025
- Financial liabilities26 · Dec 2016 to Dec 2025
- Equity23 · Dec 2015 to Dec 2025
- Other reserves (IFRS)23 · Dec 2015 to Dec 2025
- Bank overdrafts classified as cash equivalents22 · Dec 2015 to Dec 2025
- Borrowings22 · Dec 2015 to Dec 2025
- Cash and cash equivalents22 · Dec 2015 to Dec 2025
- Cash and cash equivalents if different from statement of financial position22 · Dec 2015 to Dec 2025
- Contingent liabilities recognised in business combination22 · Dec 2015 to Dec 2025
- Defined benefit obligation at present value22 · Dec 2015 to Dec 2025
- Goodwill (IFRS)22 · Dec 2015 to Dec 2025
- Intangible assets, for which impairments have been charged or reversed22 · Dec 2016 to Dec 2025
- Intangible assets other than goodwill22 · Dec 2015 to Dec 2025
- Investments in subsidiaries joint ventures and associates22 · Dec 2015 to Dec 2025
- Liability asset of defined benefit plans22 · Dec 2015 to Dec 2025
- Noncurrent provisions for employee benefits (IFRS)22 · Dec 2015 to Dec 2025
- Number of shares issued and fully paid22 · Dec 2015 to Dec 2025
- Property plant and equipment22 · Dec 2015 to Dec 2025
- Reserve of exchange differences on translation22 · Dec 2015 to Dec 2025
- Retained earnings and other reserves22 · Dec 2015 to Dec 2025
- Deferred tax liability asset21 · Dec 2016 to Dec 2025
- Net assets liabilities21 · Dec 2016 to Dec 2025
- Retained earnings21 · Dec 2016 to Dec 2025
- Trade and other current receivables (IFRS)21 · Dec 2016 to Dec 2025
IFRS142 concepts · 1,082 facts · Dec 2020 to Dec 2025
- Stockholders Equity42 · Dec 2020 to Dec 2025
- Other Comprehensive Income40 · Dec 2020 to Dec 2025
- Total Comprehensive Income40 · Dec 2020 to Dec 2025
- Issue of Equity39 · Dec 2020 to Dec 2025
- Net Income39 · Dec 2020 to Dec 2025
- Dividends Paid38 · Dec 2020 to Dec 2025
- Equity Change: Share-Based Payment Transactions38 · Dec 2020 to Dec 2025
- Equity Change: Tax on Share-Based Payments38 · Dec 2020 to Dec 2025
- Dividends Recognised as Distributions to Noncontrolling Interests37 · Dec 2020 to Dec 2025
- Equity Change: Transfers and Other Changes21 · Dec 2020 to Dec 2022
- Cash Flow Hedge Reserve Transferred to Non-Financial Assets or Liabilities14 · Dec 2023 to Dec 2024
- Equity Change: Disposal of Subsidiary14 · Dec 2022 to Dec 2024
- Accounts Payable6 · Dec 2020 to Dec 2025
- Bank Overdrafts (Cash Equivalents)6 · Dec 2020 to Dec 2025
- Capital Expenditures6 · Dec 2020 to Dec 2025
- Cash and Cash Equivalents (Cash Flow Statement)6 · Dec 2020 to Dec 2025
- Cash and Equivalents6 · Dec 2020 to Dec 2025
- Cash Generated from Operations6 · Dec 2020 to Dec 2025
- Comprehensive Income Attributable to Noncontrolling Interests6 · Dec 2020 to Dec 2025
- Comprehensive Income Attributable to Owners of Parent6 · Dec 2020 to Dec 2025
- Cost of Revenue6 · Dec 2020 to Dec 2025
- Current Derivative Financial Assets6 · Dec 2020 to Dec 2025
- Current Derivative Financial Liabilities6 · Dec 2020 to Dec 2025
- Current Tax Assets6 · Dec 2020 to Dec 2025
Segment13 concepts · 481 facts · Dec 2015 to Dec 2025
- Revenue199 · Dec 2015 to Dec 2023
- Revenue from sale of goods (IFRS)75 · Dec 2022 to Dec 2025
- Average number of employees30 · Dec 2015 to Dec 2025
- Depreciation and amortisation expense30 · Dec 2015 to Dec 2020
- Profit loss from operating activities30 · Dec 2015 to Dec 2020
- Impairment loss recognised in profit or loss29 · Dec 2015 to Dec 2020
- Goodwill26 · Dec 2016 to Dec 2025
- Reversal of impairment loss recognised in profit or loss25 · Dec 2015 to Dec 2020
- Manufacturing21 · Dec 2020 to Dec 2024
- Depreciation & Amortization5 · Dec 2016 to Dec 2020
- Operating Income5 · Dec 2016 to Dec 2020
- US [member]5 · Dec 2017 to Dec 2021
- Disposal of businesses and assets1 · Dec 2020
Geography24 concepts · 233 facts · Dec 2015 to Dec 2025
- Return on plan assets net defined benefit liability asset35 · Dec 2015 to Dec 2025
- Current tax expense income22 · Dec 2015 to Dec 2025
- UK18 · Dec 2017 to Dec 2025
- US18 · Dec 2015 to Dec 2023
- Contributions to plan by employer net defined benefit liability asset16 · Dec 2015 to Dec 2022
- Current service cost net defined benefit liability asset12 · Dec 2015 to Dec 2018
- Gain loss on remeasurement of net defined benefit liability asset12 · Dec 2015 to Dec 2018
- Interest expense income net defined benefit liability asset12 · Dec 2015 to Dec 2018
- Payments from plan net defined benefit liability asset12 · Dec 2015 to Dec 2018
- Revenue from sale of goods (IFRS)12 · Dec 2023 to Dec 2025
- Past service cost net defined benefit liability asset10 · Dec 2015 to Dec 2018
- Contributions to plan by plan participants net defined benefit liability asset9 · Dec 2015 to Dec 2018
- Increase decrease through changes in foreign exchange rates net defined benefit liability asset9 · Dec 2015 to Dec 2018
- Applicable tax rate8 · Dec 2019 to Dec 2025
- Gains losses arising from settlements net defined benefit liability asset7 · Dec 2015 to Dec 2018
- Income taxes paid refund5 · Dec 2021 to Dec 2025
- Tax expense income at applicable tax rate5 · Dec 2021 to Dec 2025
- UK [member]4 · Dec 2017 to Dec 2020
- US [member]2 · Dec 2018 to Dec 2022
- Deferred tax relating to items charged or credited directly to equity1 · Dec 2017
- Increase decrease through business combinations and disposals net defined benefit liability asset1 · Dec 2015
- Other tax effects for reconciliation between accounting profit and tax expense income1 · Dec 2017
- Proceeds from disposal of noncurrent assets or disposal groups classified as held for sale and discontinued operations1 · Dec 2018
- US and Belgium [member]1 · Dec 2017
Product4 concepts · 15 facts · Dec 2017 to Dec 2024
- Revenue9 · Dec 2019 to Dec 2023
- Revenue from sale of goods (IFRS)3 · Dec 2022 to Dec 2024
- Oncology product [member]2 · Dec 2017
- Decrease through classified as held for sale goodwill1 · Dec 2022
Guidance5 concepts · 9 facts · Jul 2026
- Effective Tax Rate Guidance2 · Jul 2026
- EPS (Diluted) Growth Guidance2 · Jul 2026
- Operating Income Growth Guidance2 · Jul 2026
- Revenue Growth Guidance2 · Jul 2026
- Revenue Guidance1 · Jul 2026
Segments
1,070 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments16 members · 481 facts
- Commercial Operations144 · Dec 2020 to Dec 2025
- Consumer Healthcare76 · Dec 2015 to Dec 2022
- Pharmaceuticals63 · Dec 2015 to Dec 2021
- Vaccines59 · Dec 2015 to Dec 2021
- Pharmaceuticals Including Research And Development24 · Dec 2015 to Dec 2020
- Pharmaceuticals Research And Development23 · Dec 2015 to Dec 2020
- Manufacturing17 · Dec 2015 to Dec 2025
- Research And Development17 · Dec 2015 to Dec 2025
- Selling General And Administration17 · Dec 2015 to Dec 2025
- Pharmaceuticals including research and development10 · Dec 2016 to Dec 2020
- Consumer healthcare6 · Dec 2016 to Dec 2021
- Pharmaceuticals6 · Dec 2016 to Dec 2021
- Vaccines6 · Dec 2016 to Dec 2021
- Pharmaceuticals And Vaccines5 · Dec 2017 to Dec 2021
- Commercial operations4 · Dec 2022 to Dec 2025
- Research and development4 · Dec 2022 to Dec 2025
Components of equity6 members · 341 facts
- Equity attributable to owners of parent61 · Dec 2020 to Dec 2025
- Retained earnings60 · Dec 2020 to Dec 2025
- Noncontrolling interests57 · Dec 2020 to Dec 2025
- Other reserves55 · Dec 2020 to Dec 2025
- Issued capital54 · Dec 2020 to Dec 2025
- Share premium54 · Dec 2020 to Dec 2025
Geographical areas9 members · 232 facts
- GB85 · Dec 2015 to Dec 2025
- US68 · Dec 2015 to Dec 2025
- Rest Of World52 · Dec 2015 to Dec 2025
- Foreign Countries11 · Dec 2015 to Dec 2025
- Country Of Domicile6 · Dec 2022 to Dec 2025
- Europe3 · Dec 2023 to Dec 2025
- International3 · Dec 2023 to Dec 2025
- US And Belgium3 · Dec 2017
- BE1 · Dec 2019
Products and services5 members · 15 facts
- HIV Oncology Immuno Inflammation Respiratory And Other6 · Dec 2021 to Dec 2024
- New And Speciality3 · Dec 2019 to Dec 2021
- Sub Total3 · Dec 2020 to Dec 2022
- Oncology Business2 · Dec 2017
- Consumer Healthcare1 · Dec 2022
Statement geographical1 member · 1 facts
- IN1 · Dec 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Management discussion (MD&A) commentary52 claims from 2 reports · Dec 2024 to Dec 2025
- Risk factors15 risks from 1 annual reports · 2025
Earnings calls
42 calls · Apr 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 28, 2026
- FY2026 Q1Apr 29, 2026
- FY2025 Q4Feb 4, 2026
- FY2025 Q3Oct 29, 2025
- FY2025 Q2Jul 30, 2025
- FY2025 Q1Apr 30, 2025
- FY2024 Q4Feb 5, 2025
- FY2024 Q3Oct 30, 2024
- FY2024 Q2Jul 31, 2024
- FY2024 Q1May 1, 2024
- FY2023 Q4Jan 31, 2024
- FY2023 Q3Nov 1, 2023
- FY2023 Q2Jul 26, 2023
- FY2023 Q1Apr 26, 2023
- FY2022 Q4Feb 1, 2023
- FY2022 Q3Nov 2, 2022
Executive media
4 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances2 · Nov 2020 to Jun 2022
- Podcasts1 · Apr 2025
- TV interviews1 · Jul 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.